Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 11,017 | 12,134 | 13,676 | 13,160 | 7,674 |
| Cost of Goods | 9,382 | 12,448 | 10,840 | 15,409 | 14,227 |
| Gross Profit | 1,635 | -314 | 2,836 | -2,249 | -6,553 |
| Operating Expenses | 83,732 | 69,999 | 64,658 | 60,733 | 59,865 |
| Operating Income | -81,715 | -69,865 | -60,982 | -62,573 | -66,191 |
| Other Income | 4,989 | 4,538 | 3,490 | 2,128 | 631 |
| Pre-tax Income | -76,726 | -65,327 | -57,492 | -60,445 | -65,560 |
| Net Income Continuous | -76,726 | -65,327 | -57,492 | -60,445 | -65,560 |
| Net Income | $-76,726 | $-65,327 | $-57,492 | $-60,445 | $-65,560 |
| EPS Basic Total Ops | -0.38 | -0.34 | -0.30 | -0.35 | -0.38 |
| EPS Basic Continuous Ops | -0.38 | -0.34 | -0.31 | -0.35 | -0.38 |
| EPS Diluted Total Ops | -0.38 | -0.34 | -0.30 | -0.35 | -0.38 |
| EPS Diluted Continuous Ops | -0.38 | -0.34 | -0.31 | -0.35 | -0.38 |
| EBITDA(a) | $-76,172 | $-66,137 | $-57,768 | $-59,584 | $-63,405 |